BioLineRx (BLRX) Q2 2025 earnings summary

Executive summary

• Progress made in evaluating early-stage oncology and rare disease assets, with a transaction targeted for 2025.

• Focus remains on pipeline expansion and leveraging expertise in drug development and regulatory affairs.

• Out-licensing agreement with Ayrmid Pharma for APHEXDA has transformed the business model and reduced operational footprint.

• Ongoing clinical trials in pancreatic cancer and sickle cell disease, with promising interim results and continued enrollment.

• Cash runway guidance extended into the first half of 2027, reflecting improved financial position.

Financial highlights

• Q2 2025 revenues were $0.3 million, reflecting royalties from Ayrmid Pharma for APHEXDA sales.

• Net loss for Q2 2025 was $3.9 million, compared to net income of $0.5 million in Q2 2024.

• Cash and equivalents at quarter-end were $28.2 million, extending runway into H1 2027.

• Research and development expenses were $2.3 million in Q2 2025, up slightly from $2.2 million in Q2 2024 due to one-time PDAC study costs.

• No sales and marketing expenses in Q2 2025 due to U.S. commercial shutdown, down from $6.4 million in Q2 2024.

Outlook and guidance

• Cash position sufficient to fund operations into the first half of 2027, improved from previous guidance.

• Targeting closure of an early clinical-stage asset transaction in 2025.

• Results from ongoing sickle cell disease gene therapy trials anticipated in H2 2025.

• Continued focus on pipeline expansion in oncology and rare diseases.